Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Ferric Maltol Suspension vs Capsules
NCT04626414Phase 1Completed
- Sponsor
- Shield Therapeutics plc
- Start
- Sep 2020
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ferric maltol in iron deficiency anemia (IDA), sponsored by Shield Therapeutics plc. Primary endpoints: Ratio of Maximum Serum Concentration (Cmax) of Total Iron in Fasted Condition at 24 hours, Ratio of Maximum Serum Concentration (Cmax) of Total Iron in Combined Periods of Fed Condition at 24 hours and 6 more. Started Sep 2020; status: completed.
02
Drugs
ferric maltol
03
Conditions
iron deficiency anemia (IDA)
Beyond the preview
Go deeper on NCT04626414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04626414.